| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Dansylglycine is a fluorescent probe that binds to drug site II on human serum albumin (HSA). It is also used for the specific determination of halogenating activity of myeloperoxidase and eosinophil peroxidase. The dansyl fluorophore provides strong fluorescence that can be used to monitor protein binding, enzyme activity, and other biochemical interactions. The compound's fluorescence properties make it valuable for various analytical and diagnostic applications.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
Dansylglycine is used as a fluorescent probe for specific determination of halogenating activity of myeloperoxidase and eosinophil peroxidase. It has established utility as a probe for drug site II on human serum albumin (HSA). The compound's fluorescence can be measured to quantify binding interactions and enzyme activities. |
| ln Vivo |
Dansylglycine has been used in vivo as a fluorescent probe for studying drug binding to human serum albumin. Its fluorescence properties allow for the detection and quantification of the compound in biological samples.
|
| Enzyme Assay |
Non-cell experimental workflows for dansylglycine typically involve fluorescence-based assays. The compound is used as a fluorescent probe for the specific determination of halogenating activity of myeloperoxidase and eosinophil peroxidase. A typical workflow includes preparing solutions of dansylglycine at various concentrations, establishing calibration curves, and measuring fluorescence intensity. The compound is also used as a probe for drug site II on HSA. Binding studies typically involve monitoring changes in fluorescence upon addition of test compounds.
|
| Cell Assay |
In vitro cell-based experimental workflows may involve using dansylglycine as a fluorescent probe to study protein binding or enzyme activity in cellular systems. Cells are cultured in appropriate medium, treated with dansylglycine, and fluorescence is measured using flow cytometry or fluorescence microscopy.
|
| Animal Protocol |
In vivo animal experimental workflows may involve administering dansylglycine to animals to study drug binding to serum albumin or to monitor enzyme activity. Blood samples are collected and analyzed for fluorescence.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of dansylglycine have been partially characterized due to its use as a probe. The compound binds to human serum albumin at drug site II. Its fluorescence properties allow for detection in biological samples.
|
| Toxicity/Toxicokinetics |
The toxicological data for dansylglycine are limited. Standard laboratory safety practices should be followed.
|
| References | |
| Additional Infomation |
Dansylglycine is a fluorescent dansyl amino acid derivative with established utility as a probe for drug site II on human serum albumin (HSA). It is a fluorescent probe for specific determination of halogenating activity of myeloperoxidase and eosinophil peroxidase. The compound is for research use only. It is not a drug and has no clinical trials or approvals.
|
| Molecular Formula |
C14H16N2O4S
|
|---|---|
| Molecular Weight |
308.35
|
| Exact Mass |
308.083
|
| CAS # |
1091-85-6
|
| PubChem CID |
70666
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.381g/cm3
|
| Boiling Point |
525.7ºC at 760mmHg
|
| Melting Point |
159ºC
|
| Flash Point |
271.7ºC
|
| Vapour Pressure |
7.01E-12mmHg at 25°C
|
| Index of Refraction |
1.643
|
| LogP |
2.74
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
472
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1=C([H])C([H])=C([H])C2C(=C([H])C([H])=C([H])C=21)N(C([H])([H])[H])C([H])([H])[H])(N([H])C([H])([H])C(=O)O[H])(=O)=O
|
| InChi Key |
QHFXORCWAQTTGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H16N2O4S/c1-16(2)12-7-3-6-11-10(12)5-4-8-13(11)21(19,20)15-9-14(17)18/h3-8,15H,9H2,1-2H3,(H,17,18)
|
| Chemical Name |
2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (405.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2431 mL | 16.2153 mL | 32.4307 mL | |
| 5 mM | 0.6486 mL | 3.2431 mL | 6.4861 mL | |
| 10 mM | 0.3243 mL | 1.6215 mL | 3.2431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
